Patents Assigned to Mochida Pharmaceutical Co., Ltd.
-
Patent number: 11472892Abstract: The present invention provides alginic acid derivatives having a group represented by general formula (I) or general formula (II) (the right side of the dashed line is excluded in each formula) at a portion of the carboxyl groups in an alginic acid. Novel alginic acid derivatives are thereby provided.Type: GrantFiled: March 27, 2019Date of Patent: October 18, 2022Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji Furusako, Tsutomu Satoh, Tomohiro Narumi
-
Patent number: 11472891Abstract: The present invention provides: an alginic acid derivative having a photocrosslinking group represented by general formula (1) for a portion of a carboxyl group of alginic acids, and a photocrosslinking alginic acid structure which is produced using this alginic acid. Due to this configuration, a novel alginic acid derivative is provided.Type: GrantFiled: February 27, 2019Date of Patent: October 18, 2022Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji Furusako, Tsutomu Satoh
-
Patent number: 11464597Abstract: [Problem] An adhesion-preventing material having a high adhesion-preventing effect has been demanded. [Solution] An adhesion-preventing material including a sterilized biocompatible sponge-like laminate, wherein the sponge-like laminate comprises a sponge-like first layer and a sponge-like second layer each of which is at least partially crosslinked with a curing agent and comprises a low-endotoxin alginic acid monovalent metal salt, the alginic acid monovalent metal salt in the first layer has a weight average molecular weight of 10,000 to 2,000,000, the alginic acid monovalent metal salt in the second layer has a weight average molecular weight of 1,000 to 1,000,000, the weight average molecular weights are measured by a GPC-MALS method after a decrosslinking treatment, and the weight average molecular weight of the alginic acid monovalent metal salt in the first layer is higher than that in the second layer.Type: GrantFiled: July 13, 2017Date of Patent: October 11, 2022Assignees: The University of Tokyo, Mochida Pharmaceutical Co., Ltd.Inventors: Taichi Ito, Seiichi Ohta, Norihiro Kokudo, Mitsuko Isaji, Satoshi Shimizu
-
Publication number: 20220280468Abstract: Disclosed is method using a composition is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.Type: ApplicationFiled: May 27, 2022Publication date: September 8, 2022Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
-
Patent number: 11426425Abstract: The present invention has an objective of providing a novel composition for treating a fibrocartilaginous tissue injury. The present invention provides a composition for treating a fibrocartilaginous tissue injury, which is to be applied to an injured fibrocartilaginous tissue part of a target and which comprises a monovalent metal salt of alginic acid, more preferably a low endotoxin monovalent metal salt of alginic acid.Type: GrantFiled: March 1, 2018Date of Patent: August 30, 2022Assignees: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido UniversityInventors: Eiji Kondo, Norimasa Iwasaki, Tomohiro Onodera, Wooyoung Kim, Yasuyuki Kawaguchi
-
Publication number: 20220193118Abstract: Provided is a composition for suppressing pain which contains a monovalent metal salt of alginic acid, the composition being applied to a nucleus pulposus cavity part to suppress pain at a surgical site and/or a surrounding site thereof which occurs after surgery. Accordingly, a composition is provided, which suppresses pain and/or inflammation at a surgical site and/or a surrounding site thereof which occurs after surgery performed on an intervertebral disc as typified by intervertebral discectomy.Type: ApplicationFiled: March 7, 2022Publication date: June 23, 2022Applicants: National University Corporation Hokkaido University, Mochida Pharmaceutical Co., LtdInventors: Hideki SUDO, Katsuro URA, Katsuhisa YAMADA
-
Patent number: 11325895Abstract: Provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea which are useful as bulk pharmaceutical crystals. Also provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea having excellent TrkA inhibitory effect, medicines and medicinal composition containing these crystals, and a method for producing these crystals.Type: GrantFiled: September 13, 2018Date of Patent: May 10, 2022Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Yuji Kawada, Fumihiko Saitoh, Hiroshi Nagasue, Tsutomu Satoh
-
Publication number: 20220009898Abstract: The present invention provides, a novel method for producing a compound represented by formula (I) and a novel method for producing a compound represented by formula (B) or a salt thereof, which are intermediates in the production of formula (I).Type: ApplicationFiled: September 27, 2021Publication date: January 13, 2022Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Hideharu UCHIDA, Tsutomu SATOH, Baoquan SUN, Chunbo SHA, Jinguang LIN, Yonghui GE, Yanliang CHEN, Bin ZHAO, Xiaomin GU, Jian LUO, Chuan CHEN, Xiaofei CAI, Jiajie YE, Jie LI, Fenglai SUN
-
Patent number: 11207286Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.Type: GrantFiled: October 18, 2019Date of Patent: December 28, 2021Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Hirosato Fujii, Motoo Yamagata
-
Publication number: 20210378650Abstract: A sheet applying device, a sheet applying system, and a sheet applying method are provided. A first sheet applying system 10 mainly includes a first sheet applying device 11 and a sheet cartridge 900. The first sheet applying device 11 mainly includes a first supporter 200 and a holder 500. The first supporter 200 mainly includes a first support shaft 210a, a second support shaft 210b, a first swing mechanism 220, a support cover 211, and a handle 300. The first support shaft 210a and the second support shaft 210b have straight cylindrical bar shapes and movably extend in parallel to each other from a proximal end side of the first sheet applying system 10 toward a distal end side of the first sheet applying system 10, in other words, in a longitudinal direction of the first supporter 200.Type: ApplicationFiled: November 18, 2019Publication date: December 9, 2021Applicant: Mochida Pharmaceutical Co., Ltd.Inventors: Hitoshi MIZUNO, Daichi TANAKA
-
Publication number: 20210380727Abstract: The present invention provides: an alginic acid derivative having a photocrosslinking group represented by general formula (1) for a portion of a carboxyl group of alginic acids, and a photocrosslinking alginic acid structure which is produced using this alginic acid. Due to this configuration, a novel alginic acid derivative is provided.Type: ApplicationFiled: February 27, 2019Publication date: December 9, 2021Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji FURUSAKO, Tsutomu SATOH
-
Publication number: 20210379004Abstract: Disclosed is method using a composition is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.Type: ApplicationFiled: June 3, 2020Publication date: December 9, 2021Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
-
Publication number: 20210340481Abstract: Provided are an alginate gel fiber for antibody production wherein an antibody-producing cell (for example, an antibody-producing CHO cell) is comprised in a core layer, and an antibody production method using the alginate gel fiber. An antibody production method is thereby additionally provided.Type: ApplicationFiled: August 9, 2019Publication date: November 4, 2021Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., THE UNIVERSITY OF TOKYOInventors: Shoji FURUSAKO, Shoji TAKEUCHI
-
Publication number: 20210283304Abstract: A non-tubular material for nerve regeneration induction, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked form produced by crosslinking a low-endotoxin bioabsorbable polysaccharide having a carboxyl group in the molecule with at least one crosslinkable reagent selected from a compound represented by general formula (I) and a salt thereof via covalent bonds; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [wherein R1 and R2 independently represent a hydrogen atom or a group represented by formula: —COCH(NH2)—(CH2)4—NH2, and n represents an integer of 2 to 18]. Thus, a medical material that can induce the regeneration of a damaged part in a nerve is provided.Type: ApplicationFiled: May 28, 2021Publication date: September 16, 2021Applicants: Tazuke Kofukai, Mochida Pharmaceutical Co., Ltd.Inventors: Yoshihisa SUZUKI, Masao TANIHARA, Mitsuko ISAJI
-
Patent number: 11117974Abstract: The present invention provides anti-presepsin polyclonal antibodies specifically binding to a peptide comprising an amino acid sequence of SEQ ID NO: 1. As a result, anti-presepsin polyclonal antibodies which have less variation in measured values between lot-to-lot differences of antibodies compared to S68 antibodies and thus suitable anti-presepsin polyclonal antibodies for presepsin measurement are provided.Type: GrantFiled: August 25, 2015Date of Patent: September 14, 2021Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Publication number: 20210267927Abstract: A self-emulsifying composition contains: 70 to 90% by weight in total of one or more compounds selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 1 to 29% by weight of an emulsifying agent selected from among a polyoxyethylene sorbitan fatty acid ester, a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyl castor oil; and 0.5 to 6% by weight of water when the composition is defined to be 100% by weight as a whole. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.Type: ApplicationFiled: May 10, 2021Publication date: September 2, 2021Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shigeru KIMURA, Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA
-
Patent number: 11084883Abstract: The present invention provides anti-presepsin polyclonal antibodies specifically binding to a peptide comprising an amino acid sequence of SEQ ID NO: 1. As a result, anti-presepsin polyclonal antibodies which have less variation in measured values between lot-to-lot differences of antibodies compared to S68 antibodies and thus suitable anti-presepsin polyclonal antibodies for presepsin measurement are provided.Type: GrantFiled: August 25, 2015Date of Patent: August 10, 2021Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Patent number: 11052174Abstract: A non-tubular material for nerve regeneration induction, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked form produced by crosslinking a low-endotoxin bioabsorbable polysaccharide having a carboxyl group in the molecule with at least one crosslinkable reagent selected from a compound represented by general formula (I) and a salt thereof via covalent bonds; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [wherein R1 and R2 independently represent a hydrogen atom or a group represented by formula: —COCH(NH2)—(CH2)4—NH2, and n represents an integer of 2 to 18]. Thus, a medical material that can induce the regeneration of a damaged part in a nerve is provided.Type: GrantFiled: March 14, 2017Date of Patent: July 6, 2021Assignees: Mochida Pharmaceutical Co., Ltd.Inventors: Yoshihisa Suzuki, Masao Tanihara, Mitsuko Isaji
-
Publication number: 20210186882Abstract: The present invention provides: a freeze-dried composition which comprises (a) a monovalent metal alginate and (b) a salt selected from a monovalent metal salt and an ammonium salt; and a method of producing a freeze-dried monovalent metal alginate composition which comprises the steps of freezing an aqueous solution formed by dissolving at least the component (a) and the component (b), performing first drying, and then performing second drying as desired to reduce a water content to 3% by mass or less. This is a freeze-dried monovalent metal alginate composition with suppressed viscosity decrease with the lapse of time.Type: ApplicationFiled: March 8, 2021Publication date: June 24, 2021Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shuichi ENDO, Naoya YOSHIOKA
-
Patent number: 11041864Abstract: Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients.Type: GrantFiled: January 10, 2012Date of Patent: June 22, 2021Assignees: LSI MEDIENCE CORPORATION, MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Takeshi Matsuya, Yoshikazu Okamura, Ralf Thomae, Eberhard Spanuth, Boris Ivandic, Kamon Shirakawa, Shigeatsu Endo